{"filings":[{"id":96607,"accession_number":"0001628280-26-031719","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prime Medicine Q1 net loss $49.1M; progress on Wilson, AATD programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $49.1M in Q1 2026 vs $51.9M in Q1 2025; R&D down to $34.1M.","Cash position $149.2M as of March 31, 2026, providing runway into 2027.","On track to file IND/CTA for PM577 (Wilson Disease) in H1 2026 and PM647 (AATD) mid-2026.","Appointed Svetlana Makhni as CFO in April 2026; regulatory dialogue ongoing for PM359 BLA.","Initial clinical data from PM577 and PM647 expected in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96606,"accession_number":"0001628280-26-025372","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Prime Medicine appoints Svetlana Makhni as CFO effective April 16, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Svetlana Makhni named CFO; base salary $495K, sign-on bonus $40K, target bonus 40%.","Granted option to purchase 800K shares (time-based vesting over 4 years) and 100K milestone-based option.","Allan Reine steps down as principal financial officer but remains CEO.","Makhni has 20+ years biotech/healthcare CFO and investment banking experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110644,"accession_number":"0001628280-26-013565","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prime Medicine FY2025 net loss $201.1M; WD/AATD IND filings on track, CGD BLA planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $201.1M for FY2025, cash $191.4M providing runway into 2027.","On track to file IND/CTA for Wilson Disease (1H 2026) and AATD (mid-2026); initial clinical data expected 2027.","Engaging FDA for PM359 in CGD; plans BLA based on Phase 1/2 data published in NEJM, targeting accelerated approval.","Workforce reduction and deprioritization of CGD program to focus on in vivo liver franchise.","CF program preclinical proof-of-concept data expected 2026; BMS CAR-T collaboration continues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110643,"accession_number":"0001628280-26-001773","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Prime Medicine posts updated corporate presentation; no specific new data disclosed in exhibit snippet","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished an updated corporate presentation dated January 2026 under Item 7.01.","Presentation available at investors.primemedicine.com; exhibit text truncated, no pipeline or financial details visible.","No material changes, guidance, or clinical updates extractable from the filed excerpt.","Presentation likely covers prime editing platform; specifics remain unknown to investors from this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127269,"accession_number":"0001628280-25-050415","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prime Medicine Q3 net loss $50.6M; cash $227M funds into 2027; AATD candidate nominated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $50.6M vs $52.5M in Q3 2024; R&D spend $44.0M (+9% YoY) driven by license costs.","Cash and investments $227M; company expects runway into 2027 under current plans.","Nominated PM647 as AATD development candidate; IND/CTA on track for mid-2026 with clinical data in 2027.","Wilson's Disease program PM577 on track for IND/CTA in H1 2026; initial data expected in 2027.","Appointed Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer to lead strategy and partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":3794000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144063,"accession_number":"0001894562-25-000056","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Prime Medicine posts updated corporate presentation; no quantitative details from exhibit.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation posted to investor website on September 8, 2025.","Presentation is dated September 2025 and focuses on Prime Editing platform.","No specific financial figures, pipeline updates, or new data are visible in the limited exhibit text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144062,"accession_number":"0001628280-25-038617","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prime Medicine Q2: positive CGD clinical data, $144M offering, cash runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First clinical proof-of-concept for Prime Editing: two patients in CGD trial showed restored NADPH oxidase activity above clinical benefit threshold.","Completed $144.2M follow-on offering in August 2025; cash balance pro-forma $259.6M as of June 30, 2025.","Secured up to $24M from Cystic Fibrosis Foundation to advance CF program targeting G542X mutation.","Allan Reine named CEO in May 2025; strategic restructuring and workforce reduction expected to cut cash needs by half through 2027.","Net loss of $52.6M in Q2 2025 (vs. $55.3M in Q2 2024); R&D expenses down to $41.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":2569000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144061,"accession_number":"0001628280-25-037840","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Prime Medicine shareholders approve repricing of up to 8.3M stock options to $4.04/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved one-time repricing of eligible options held by employees, execs, and board; exercise price reduced to $4.04 (Aug 1 closing price).","Covers up to 8,285,387 shares; options revert to original price if exercised before 1-yr (employees) or 18-mo (executives/board) retention period unless certain conditions.","Final vote: 71.6M for, 13.5M against, 0.1M abstain.","CEO Allan Reine and other named exec officers are eligible optionholders.","Repricing intended as retention mechanism; original terms except exercise price remain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144060,"accession_number":"0001628280-25-037076","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Prime Medicine prices $125M equity offering; net proceeds ~$120.2M for R&D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 38M shares at $3.30/share; underwriters have 30-day option for 5.7M additional shares.","Estimated net proceeds of $120.2M after underwriting discounts and expenses.","Proceeds to fund Wilson's Disease and Alpha-1 Antitrypsin Deficiency programs; remainder for working capital.","Underwriting led by TD Securities and BMO Capital Markets; expected close August 1, 2025.","Cystic Fibrosis Foundation to purchase 1,818,181 shares without any underwriting discounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144059,"accession_number":"0001628280-25-036705","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Prime Medicine reports ~$101.8M cash as of June 30; terminates ATM prospectus","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary cash, equivalents, and short-term investments ~$101.8M at June 30, 2025; plus $13.7M restricted cash.","Terminated ATM prospectus under S-3 effective July 30; no further sales pending new filing.","Sales agreement with Jefferies remains in force but ATM program currently inactive.","Updated July 2025 corporate presentation posted on company website; includes pipeline updates.","Company expects to report complete Q2 results in Form 10-Q; estimates subject to final adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144058,"accession_number":"0001628280-25-034971","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Prime Medicine CSO Jeremy Duffield steps down effective July 15, 2025; retains as consultant through Mar 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeremy Duffield, M.D., Ph.D., FRCP, resigns as Chief Scientific Officer effective July 15, 2025.","Company to enter Separation Agreement providing severance per his 2022 employment agreement.","Duffield retained as consultant from July 15, 2025 through March 31, 2026.","All outstanding equity awards continue vesting during the Advisory Period.","No successor named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162359,"accession_number":"0001628280-25-029646","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Prime Medicine shareholders elect Cahill and Nelsen as Class III directors, ratify PwC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Thomas Cahill elected with 74,446,103 For, 8,336,569 Withheld, 15,311,067 broker non-votes.","Robert Nelsen elected with 70,607,668 For, 12,175,004 Withheld, 15,311,067 broker non-votes.","Ratification of PricewaterhouseCoopers as auditor passed: 98,008,974 For, 42,555 Against, 42,210 Abstentions.","Quorum of 98,093,739 shares present (74.8% of 131,160,842 outstanding shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162358,"accession_number":"0001193125-25-122156","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Prime Medicine CEO Gottesdiener resigns; Reine named CEO; positive CGD data; restructures to liver focus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Keith Gottesdiener resigned as CEO and board member; CFO Allan Reine appointed CEO and to board, effective May 19, 2025.","Jeff Marrazzo named Executive Chair of the board.","First clinical data for PM359 in CGD: 58% DHR positivity at Day15, 66% at Day30, well above 20% threshold; rapid engraftment.","Company to deprioritize CGD programs, seek partner for PM359; focus on Wilson's Disease and AATD with IND/CTA in 1H2026 and mid-2026.","Workforce reduction and cost cutting to reduce cash needs; Beam arbitration ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162357,"accession_number":"0001628280-25-023482","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prime Medicine Q1 2025 net loss $51.9M; cash $158.3M; pipeline on track for CGD data in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $51.9M (vs $45.8M Q1 2024); R&D $40.6M, G&A $13.3M.","Cash, equivalents, investments $158.3M as of March 31, 2025, down from $204.5M at Dec 31, 2024.","Initial Phase 1/2 data for PM359 (p47 phox CGD) expected in 2025.","IND/CTA for PM577 (Wilson's Disease) on track for 1H 2026; AATD program unveiled with IND/CTA mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":1454000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180373,"accession_number":"0001193125-25-056122","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Prime Medicine unveils preclinical AATD program with up to 72% gene correction, IND/CTA expected mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AATD program targets E342K (Pi*Z) mutation in SERPINA1 gene using LNP-delivered Prime Editors.","In humanized mice, up to 72% precise correction of SERPINA1 in hepatocytes, restoring >95% serum AAT to corrected isoform.","Serum M-AAT levels well above 20µM, indicating restoration to normal levels in mouse model.","Company expects to file IND and/or CTA for AATD program in mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180372,"accession_number":"0001628280-25-008873","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prime Medicine reports FY2024 net loss $195.9M; cash $204.5M; PM359 data in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $195.9M for FY2024 vs $198.1M in FY2023; R&D expenses $155.3M.","Cash, equivalents, and investments $204.5M at Dec 31, 2024, up from $135.2M.","Initial clinical data from PM359 Phase 1/2 for p47 phox CGD expected in 2025.","IND/CTA filing for PM577 (Wilson's Disease) planned for first half of 2026.","Cash runway expected into first half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":2983000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180371,"accession_number":"0001628280-25-001244","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Prime Medicine posts updated corporate presentation; details not fully disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted Jan 13, 2025 on company website; included as exhibit but content truncated.","No specific financial or program updates visible in provided filing text.","Presentation titled 'Delivering on the promise of Prime Editing' suggests continued focus on gene editing platform.","Further details may be available on investor relations page."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197191,"accession_number":"0001628280-24-047119","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prime Medicine Q3 net loss $52.5M; BMS collaboration provides $110M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $52.5M in Q3 2024 vs. $50.7M in Q3 2023; R&D expenses $40.3M, G&A $14.1M.","Pro-forma cash $244.6M, sufficient to fund operations into 1H 2026.","Entered strategic collaboration with Bristol Myers Squibb for ex vivo T-cell therapies; $110M upfront (including $55M equity investment), potential milestones >$3.5B.","Wilson's Disease program initiated IND-enabling activities; IND/CTA filing expected 1H 2026.","Phase 1/2 trial of PM359 for p47 phox CGD ongoing; initial clinical data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":800000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197190,"accession_number":"0001628280-24-043500","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Prime Medicine reports up to 80% gene correction in Wilson's Disease; on track for IND-enabling","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GalNAc-LNP delivery of Prime Editors achieved up to 80% precise correction of ATP7B H1069Q mutation in humanized mice.","In NHPs, up to 51% precise editing of liver cells with surrogate H1069Q Prime Editor; no off-target edits detected.","IND-enabling activities for Wilson's Disease program to start in 4Q 2024; IND/CTA filing expected 1H 2026.","GSD1b program data: up to 85% precise liver cell editing in NHPs, durable to 44 weeks, no safety concerns.","Universal liver-targeted LNP platform shows modularity; can be adapted to other rare and non-rare liver indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213442,"accession_number":"0001628280-24-041541","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Prime Medicine inks $110M upfront BMS collaboration, refocuses pipeline, cash runway to H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $55M upfront + $55M equity investment ($5.00/share) from BMS for exclusive license to Prime Editing for ex vivo T-cell therapies.","Up to >$3.5B in milestones ($1.4B development, >$2.1B commercialization) plus tiered royalties; BMS locked up shares until Sep 2027.","Pipeline focus: Phase 1/2 CGD data expected in 2025; Wilson's Disease IND/CTA planned for H1 2026.","X-linked CGD program added using PASSIGE technology; cystic fibrosis work continues with CFF funding.","Cost savings plus BMS upfront extend cash runway into first half of 2026 (previously not guided beyond 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213441,"accession_number":"0001628280-24-035886","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prime Medicine Q2 net loss $55.3M; FDA clears PM359 for CGD Phase 1/2 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA cleared IND for PM359 (Prime Editor for chronic granulomatous disease); Phase 1/2 trial initiating, initial data expected 2025.","Net loss $55.3M vs $42.4M YoY; R&D expenses $43.1M up from $34.6M; G&A $12.6M vs $10.7M.","Cash, equivalents, investments & restricted cash $176.4M as of June 30, 2024 (up from $135.2M Dec 31, 2023).","Promoted Mohammed Asmal, M.D., Ph.D. to Chief Medical Officer, effective immediately; he was SVP Head of Clinical since 2022.","Pipeline milestones: liver IND/CTA expected H2 2025–H1 2026; ocular candidate nomination for RHO-RP in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":591000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232642,"accession_number":"0001628280-24-027816","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Prime Medicine stockholders elect directors, approve officer liability limitation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Wendy Chung, Kaye Foster, Keith Gottesdiener, and Jeffrey Marrazzo as Class II directors.","Approved certificate amendment to limit officer liability as permitted by Delaware law with 91.5M votes for.","Ratified PricewaterhouseCoopers as independent auditor for FY2024 with 106.9M votes for.","Annual meeting held June 12, 2024; quorum of 107.1M shares represented.","All proposals passed; no dissident activity or unexpected vote outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232641,"accession_number":"0001628280-24-024530","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Prime Medicine adopts Second Amended and Restated Bylaws with updated stockholder proposal procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Second A&R Bylaws effective May 17, 2024, superseding prior bylaws.","Revises advance notice procedures for stockholder proposals and director nominations.","Addresses universal proxy rules; requires compliance with Rule 14a-19 for non-Board nominees.","Clarifies Board meeting procedures including postponing, rescheduling, canceling stockholder meetings.","Updates routine, technical, and non-substantive provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232640,"accession_number":"0001628280-24-022466","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prime Medicine Q1 net loss $45.8M; FDA clears IND for CGD Prime Editing therapy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $45.8M (vs $39.4M Q1 2023); cash $224.2M as of March 31, 2024.","FDA cleared IND for PM359 for chronic granulomatous disease—first Prime Editing product to enter clinic.","Phase 1/2 trial planned; initial clinical data expected in 2025.","Appointed Tony Coles, M.D. as senior advisor; brings biopharma leadership.","Presented preclinical data at ASGCT supporting specificity and delivery of Prime Editing platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":591000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250884,"accession_number":"0001628280-24-008113","cik":1894562,"company_name":"Prime Medicine, Inc.","ticker":"PRME","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prime Medicine reports FY2023 net loss of $198.1M; eyes IND/CTA for CGD in 1H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $198.1M in FY2023 ($121.8M in FY2022); R&D expenses $147.9M up from $86.7M.","Cash, equivalents, investments, restricted cash $135.2M at Dec 31, 2023, vs $307.4M year earlier.","Closed upsized public offering in Feb 2024, gross proceeds ~$161.0M at $6.25 per share.","Expects to file IND/CTA for PM359 (CGD) in 1H 2024; initial clinical data anticipated in 2025.","Received Orphan Drug Designation for PM359; $15M CF Foundation funding for CF Prime Editors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":590600980.928303,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}